CTSB and invasive breast carcinoma: Consistently, ErbB2-positive primary breast tumors exhibit increased mRNA and protein expression of cathepsins B and L. Supporting the in vivo connection of ErbB2 activation and cathepsins B and L, the positive correlation between ErbB2 and cathepsin B and L expression in invasive breast cancer was found to be significant [7].